Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 4189678, 7 pages
https://doi.org/10.1155/2017/4189678
Clinical Study

Effects of FMO3 Polymorphisms on Pharmacokinetics of Sulindac in Chinese Healthy Male Volunteers

1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
2Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China
3Department of Pediatrics, Xiangya Hospital, Central South University, Changsha 410008, China
4Department of Neurology, Xiangya Hospital, Central South University, Changsha 410078, China
5Tang Center for Herbal Medicine Research, The Pritzker School of Medicine, University of Chicago, 5841 South Maryland Avenue, MC 4028, Chicago, IL 60637, USA

Correspondence should be addressed to Wei-Hua Huang; moc.621@25843ruovaedne and Zhi-Rong Tan; moc.361@rznat

Received 31 August 2016; Revised 1 November 2016; Accepted 17 November 2016; Published 26 February 2017

Academic Editor: Heiko Reutter

Copyright © 2017 Yong-Jun Tang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Castellsague, N. Riera-Guardia, B. Calingaert et al., “Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS Project),” Drug Safety, vol. 35, no. 12, pp. 1127–1146, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. V. Rollason, C. F. Samer, Y. Daali, and J. A. Desmeules, “Prediction by pharmacogenetics of safety and efficacy of non-steroidal anti-inflammatory drugs: a review,” Current Drug Metabolism, vol. 15, no. 3, pp. 326–343, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. D. E. Duggan, L. E. Hare, C. A. Ditzler, B. W. Lei, and K. C. Kwan, “The disposition of sulindac,” Clinical Pharmacology and Therapeutics, vol. 21, no. 3, pp. 326–335, 1977. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Kitamura, K. Nakatani, K. Ohashi et al., “Extremely high drug-reductase activity based on aldehyde oxidase in monkey liver,” Biological and Pharmaceutical Bulletin, vol. 24, no. 7, pp. 856–859, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. M. S. Motika, J. Zhang, X. Zheng, K. Riedler, and J. R. Cashman, “Novel variants of the human flavin-containing monooxygenase 3 (FMO3) gene associated with trimethylaminuria,” Molecular Genetics and Metabolism, vol. 97, no. 2, pp. 128–135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Yamazaki and M. Shimizu, “Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities,” Biochemical Pharmacology, vol. 85, no. 11, pp. 1588–1593, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. J. R. Cashman, “Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism,” Current Drug Metabolism, vol. 1, no. 2, pp. 181–191, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. W.-G. Chung, C.-S. Park, H.-K. Roh, W.-K. Lee, and Y.-N. Cha, “Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450,” Japanese Journal of Pharmacology, vol. 84, no. 2, pp. 213–220, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Störmer, I. Roots, and J. Brockmöller, “Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity,” British Journal of Clinical Pharmacology, vol. 50, no. 6, pp. 553–561, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Sachse, S. Ruschen, M. Dettling et al., “Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism,” Clinical Pharmacology and Therapeutics, vol. 66, no. 4, pp. 431–438, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. I. M. Hisamuddin, M. A. Wehbi, A. Chao et al., “Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis,” Clinical Cancer Research, vol. 10, no. 24, pp. 8357–8362, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. S. B. Koukouritaki, M. T. Poch, E. T. Cabacungan, D. G. McCarver, and R. N. Hines, “Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants,” Molecular Pharmacology, vol. 68, no. 2, pp. 383–392, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. J.-H. Kang, W.-G. Chung, K.-H. Lee et al., “Phenotypes of flavin-containing monooxygenase activity determined by ranitidine N-oxidation are positively correlated with genotypes of linked FMO3 gene mutations in a Korean population,” Pharmacogenetics, vol. 10, no. 1, pp. 67–78, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Zschocke, D. Kohlmueller, E. Quak, T. Meissner, G. F. Hoffmann, and E. Mayatepek, “Mild trimethylaminuria caused by common variants in FIMO3 gene,” Lancet, vol. 354, no. 9181, pp. 834–835, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Nagashima, M. Shimizu, H. Yano et al., “Inter-individual variation in flavin-containing monooxygenase 3 in livers from Japanese: correlation with hepatic transcription factors,” Drug Metabolism and Pharmacokinetics, vol. 24, no. 3, pp. 218–225, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Shimizu, H. Yano, S. Nagashima et al., “Effect of genetic variants of the human flavin-containing monooxygenase 3 on N- and S-oxygenation activities,” Drug Metabolism and Disposition, vol. 35, no. 3, pp. 328–330, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. D.-C. Hao, J. Sun, B. Furnes et al., “Haplotype frequency distribution and linkage disequilibrium analysis of single nucleotide polymorphisms at the human FMO3 gene locus,” Biochemical Genetics, vol. 44, no. 7-8, pp. 391–407, 2006. View at Google Scholar · View at Scopus
  18. D. Hao, J. Sun, B. Furnes et al., “Allele and genotype frequencies of polymorphic FMO3 gene in two genetically distinct populations,” Cell Biochemistry and Function, vol. 25, no. 4, pp. 443–453, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. W.-H. Huang, L. Shao, S.-X. Li et al., “Simultaneous determination of sulindac and its metabolites sulindac sulfide and sulindac sulfone in human plasma by a sensitive UPLC-PDA method for a pharmacokinetic study,” Analytical Methods, vol. 6, no. 13, pp. 4679–4685, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. C.-S. Park, J.-H. Kang, W.-G. Chung et al., “Ethnic differences in allelic frequency of two flavin-containing monooxygenase 3 (FMO3) polymorphisms: linkage and effects on in vivo and in vitro FMO activities,” Pharmacogenetics, vol. 12, no. 1, pp. 77–80, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. L.-P. Zhou, Z.-R. Tan, H. Chen et al., “Effect of two-linked mutations of the FMO3 gene on itopride metabolism in Chinese healthy volunteers,” European Journal of Clinical Pharmacology, vol. 70, no. 11, pp. 1333–1338, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. J. R. Cashman, B. R. Akerman, S. M. Forrest, and E. P. Treacy, “Population-specific polymorphisms of the human FMO3 gene: significance for detoxication,” Drug Metabolism and Disposition, vol. 28, no. 2, pp. 169–173, 2000. View at Google Scholar · View at Scopus
  23. J. R. Cashman and J. Zhang, “Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation,” Drug Metabolism and Disposition, vol. 30, no. 10, pp. 1043–1052, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Cruz-Correa and F. M. Giardiello, “Familial adenomatous polyposis,” Gastrointestinal Endoscopy, vol. 58, no. 6, pp. 885–894, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. J.-Q. Sheng, W.-J. Cui, L. Fu et al., “APC gene mutations in Chinese familial adenomatous polyposis patients,” World Journal of Gastroenterology, vol. 16, no. 12, pp. 1522–1526, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. I. M. Hisamuddin, M. A. Wehbi, B. Schmotzer et al., “Genetic polymorphisms of Flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 10, pp. 2366–2369, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. D. E. Duggan, K. F. Hooke, E. A. Risley, T. Y. Shen, and C. G. Arman, “Identification of the biologically active form of sulindac,” Journal of Pharmacology and Experimental Therapeutics, vol. 201, no. 1, pp. 8–13, 1977. View at Google Scholar · View at Scopus
  28. F. Etienne, L. Resnick, D. Sagher, N. Brot, and H. Weissbach, “Reduction of Sulindac to its active metabolite, sulindac sulfide: assay and role of the methionine sulfoxide reductase system,” Biochemical and Biophysical Research Communications, vol. 312, no. 4, pp. 1005–1010, 2003. View at Publisher · View at Google Scholar · View at Scopus